INTRODUCTION
Dopamine is a major neurotransmitter in the mammalian brain. This transmitter exerts its pleiotropic actions through interactions with two classes of dopamine receptors: the D1 class (D1 and D5 subtypes) and the D2 class (D2, D3, and D4 subtypes). The former is coupled to Gas-proteins, whereas the latter is generally coupled to Gai/o-proteins. Through Gai/o-proteins, the D2 class of receptors inhibits adenylyl cyclase and the downstream formation of cAMP (Neve et al., 2004) . Remarkably, among all dopamine receptor subtypes, the dopamine D3 receptor (D3R), one of the lesser-investigated subtypes, shows a unique distribution pattern in the forebrain. D3Rs are preferentially expressed in the mesolimbic dopaminergic projection areas, including the nucleus accumbens (NAc) (Sokoloff et al., 1990; Bouthenet et al., 1991) . This specific localization of D3Rs suggests a significant role of the receptor in the control of reward, motivation, cognition, emotion, and extrapyramidal motor functions. Moreover, malfunction of D3Rs has been frequently associated with the pathogenesis of various mental illnesses such as schizophrenia, depression, and substance addiction (reviewed in Heidbreder et al., 2005; Sokoloff et al., 2006; Richtand, 2006) . Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) is an enzyme that is abundant in brain cells, especially at synaptic sites (Kelly et al., 1984) . The enzyme is removed from its autoinhibitory state and activated by the binding of Ca 2+ and calmodulin (CaM) . Activated CaMKII accesses and phosphorylates not only exogenous substrates but also its own autophosphorylation site (T286 in the a isoform) within the autoregulatory domain. The autophosphorylation renders a Ca 2+ /CaM-independent (autonomous) kinase activity even after the initial Ca 2+ stimulus subsides (Hudmon and Schulman, 2002; Colbran and Brown, 2004; Griffith, 2004 ). As such, CaMKII integrates and prolongs the information conveyed by diverse forms of Ca 2+ transients and serves as a dynamic regulator that decodes activity-dependent Ca 2+ signals into various forms of synaptic activity and plasticity (reviewed in Hudmon and Schulman, 2002; Lisman et al., 2002; Colbran and Brown, 2004) .
The multifunctional nature of CaMKII also stems from its interactions with various binding partners in defined subcellular regions (Colbran, 2004) . Through direct protein-protein interactions, CaMKII vigorously regulates expression and function of interacting partners and vice versa. In searching for new targets of CaMKII at synaptic sites, we identify the limbic D3R as a direct substrate of CaMKII. We show that CaMKIIa interacts directly with the N-terminal region of the third intracellular loop of D3Rs in a Ca 2+ -and autophosphorylation-sensitive manner in vitro. This interaction allows CaMKII to phosphorylate D3Rs at a selective serine residue. In accumbal neurons in vivo, Ca 2+ stimulates the association of CaMKII with D3Rs and increases serine phosphorylation of D3Rs, resulting in suppression of D3R function. The CaMKII-mediated inhibition of D3Rs plays a significant role in regulating behavioral responsiveness to cocaine. Collectively, Precipitated proteins from pull-down assays (C, E, and F) and proteins bound to CaMKIIa or D3R IL3 from in vitro binding assays (H-J) were visualized with immunoblots (IB) using the specific antibodies as indicated.
itated D3Rs in accumbal lysates, whereas GST-CaMKIIa RD , GST-CaMKIIa AD , and GST-CaMKIV did not ( Figure 1E ). None of the GST-fusion proteins precipitated dopamine D1 receptors (D1Rs) ( Figure 1F ). Thus, the primary CaMKIIa region for the interaction with D3Rs is restricted to CaMKIIa CD . All blots were probed in parallel with a GST antibody to ensure equivalent protein loading (data not shown).
To define whether the CaMKIIa-D3R interaction is direct, and to reveal the accurate region of D3R IL3 involved in the interaction, we conducted in vitro binding assays with purified proteins ( Figure 1G-1J ). We found that CaMKIIa bound to immobilized GST-D3R IL3 and GST-D3R IL3 (R210-P239), but not to other GST-D3R IL3 fragments ( Figure 1H ). No CaMKIIa bound to GST-D2R IL3 (I210-V270) ( Figure 1I ). In the reverse experiment, D3R IL3 bound to immobilized GST-CaMKIIa and GST-CaMKIIa CD , but not to GST-CaMKIIa RD , GST-CaMKIIa AD , or GST-CaMKIV ( Figure 1J ). These results demonstrate that CaMKIIa directly binds to D3Rs in vitro. The R210-P239 fragment, a 30 amino acid region at the N terminus of D3R IL3 , contains a site critical for binding to the catalytic domain of CaMKIIa.
Ca
2+ Enhances the Binding of CaMKIIa to D3Rs Binding of Ca 2+ /CaM to the regulatory domain of CaMKII is an essential step for releasing autoinhibition and activating the enzyme. Thus, Ca 2+ usually regulates the binding properties of CaMKII (Bayer et al., 2001; Colbran and Brown, 2004) . To determine if Ca 2+ affects the CaMKIIa association with D3Rs, we tested the capacity of CaMKIIa to bind to GST-D3R IL3 in the presence of Ca 2+ , CaM, or both. Similar to the results from the above in vitro binding assays performed in the absence of exogenously added Ca 2+ /CaM, CaMKIIa showed a low level of constitutive binding to GST-D3R IL3 (L1 in Figure 2A) . Interestingly, the addition of Ca 2+ (0.5 mM) and CaM (1 mM) together, but not Ca 2+ or
CaM alone, significantly increased the amount of CaMKIIa bound to D3R IL3 (L4 versus L2 and L3 in Figures 2A and 2B) . This increase was prevented by adding the Ca 2+ chelator EGTA at 1 mM (L5 in Figure 2A ), and could occur to CaMKIIa that was not autophosphorylated at T286, as evidenced by the fact that no T286-autophosphorylated CaMKIIa (pCaMKIIa) was detected in these binding assays with a phospho-specific antibody, due to the absence of ATP throughout the reaction (middle panel of Figure 2A ). These results demonstrate that activation of CaMKIIa by Ca 2+ /CaM was sufficient to enhance its affinity for D3Rs.
Consistent with this, an increase in the CaMKIIa-D3R IL3 binding was observed only with the wild-type (WT) CaMKIIa, but not with the Ca 2+ /CaM binding-defective CaMKIIa mutant T305/ 306D ( Figures 2C and 2D ) (Colbran and Soderling, 1990 observed, whereas CaM bound to GSTCaMKIIa in a Ca 2+ -dependent fashion ( Figure 2F ). /CaM signal subsides (Meyer et al., 1992) . A series of experiments was carried out to determine the influence of T286 autophosphorylation on the CaMKIIa-D3R binding. The unphosphorylated WT kinase exhibited constitutive and enhanced binding to D3R IL3 in the absence and presence of Ca 2+ /CaM, respectively ( Figure 3A) . Interestingly, WT CaMKIIa that was activated by Ca 2+ /CaM and autophosphorylated at T286 prior to the binding assays showed a further enhanced level of binding (L3 and L4 in Figure 3A ) as compared with unphosphorylated WT, regardless of the presence or absence of Ca 2+ /CaM in the binding assays ( Figures 3A and 3D ). An autophosphorylationdefective mutant, T286A, showed the same level of binding to D3Rs in the presence or absence of ATP ( Figures 3B and 3D Figure 3E ). The addition of EGTA substantially inhibited the CaMKIIa binding. However, this inhibition occurred only when EGTA was added in the early phase (<2 min, L4-L6 in Figure 3E ). When the binding reaction lasted long enough (2-15 min), EGTA was no longer effective (L7 and L8 in Figure 3E ). The D3R IL3 -bound enzyme from the ATP-containing assays was autophosphorylated at T286, and the level of this autophosphorylation paralleled well with the capacity of the enzyme in binding to D3Rs at different EGTA-adding times ( Figure 3E ). These data suggest that the CaMKIIa binding to D3Rs and T286 autophosphorylation are initially reversible, but become Ca 2+ /CaM independent when the kinase transforms to an autonomous state. Like the unphosphorylated enzyme, autophosphorylated CaMKIIa bound to the same N-terminal region (R210-P239) of D3R IL3 ( Figure 3F ). This region was therefore further analyzed to identify a sufficient binding motif. A panel of peptides derived from this region was used to compete with the R210-P239 fragment for binding to CaMKIIa. It was found that four out of six peptides (P1, P2, P3, and P5) blocked the binding of GST-D3R IL3 (R210-P239) to active CaMKIIa ( Figure S2A ) or autophosphorylated CaMKIIa ( Figure 3G ). These four peptides, when used in a biotinylated form, pulled down CaMKIIa ( Figure S2B ). Thus, a 14 residue motif (RILTRQNSQCISIR) contained by all four peptides constitutes a core motif for CaMKIIa binding. Notably, this motif is highly conserved among mammals.
Autophosphorylation of CaMKIIa

CaMKII Phosphorylates S229 in D3R IL3
A comparison of the amino acid sequences revealed a remarkable homology between the CaMKIIa-binding region in D3R IL3 and the sequences spanning a T286 pseudosubstrate region in CaMKIIa (Yang and Schulman, 1999) , S1303 in NR2B (Strack et al., 2000) , and an S/T site in two classical CaMKII substrates, autocamtide-2 and syntide-2 ( Figure 4A ). This suggested that D3R IL3 might serve as a phosphorylation substrate of CaMKII. Indeed, CaMKIIa phosphorylated GST-D3R IL3 , but not GST, in the presence of Ca 2+ /CaM ( Figure 4B ). Similarly, CaMKIIa phosphorylated the GST-D3R IL3 (R210-P239) fragment (Figure 4C) . This phosphorylation was rapid ( Figure 4D ) and comparable to the phosphorylation of an NR2B fragment ( Figure S3A ). The kinetic parameter, Km, was notably low, 65.9 ± 1.2 nM ( Figure 4E ), suggesting that D3R IL3 , like NR2B (Omkumar et al., 1996) , acts as a high-affinity substrate. This highaffinity nature implies that phosphorylation of D3R IL3 could occur under physiological conditions. In support of this, GST-D3R IL3 (R210-P239) was phosphorylated at two physiological Ca 2+ concentrations ( Figure S3B ).
To identify accurate phosphorylation sites within the R210-P239 fragment, we used a series of synthetic peptides with or without mutations of two known serine sites in this fragment (S229 and S233). Figure 4F shows that the WT S229/233 peptide substrate was phosphorylated by CaMKIIa to a considerable stoichiometry (0.81 mol of phosphate/mol of substrate). Mutation of S233 to alanine (S233A) did not affect the phosphorylation. In contrast, mutation of S229 to alanine (S229A) or S229/233 to alanine (S229/233A) completely abolished the phosphorylation. Thus, S229 rather than S233 or T225 is the site of phosphorylation. The fact that S229 lies within the CaMKII binding motif in D3R IL3 and aligns with a phospho-S/T site predicted from the consensus CaMKII phosphorylation sequence, (I/L)XRXX(S/T) , is noteworthy. The results from tandem mass spectrometry analysis of tryptic digests of CaMKII-phosphorylated GST-D3R IL3 conclusively identified S229 as a phosphorylation site (data not shown).
Although the CaMKIIa binding domain in D3R IL3 aligns with the substrate recognition motif and contains a high-affinity phosphorylation site (S229), a classical enzyme-substrate binding mechanism does not appear to be involved in the CaMKIIa binding to D3R IL3 . This is supported by the finding that syntide-2 (a model peptide substrate for CaMKII) at concentrations up to 400 mM (>30 times the Km for phosphorylation; Hashimoto and Soderling, 1987) failed to compete for the CaMKIIa binding to D3R IL3 ( Figure S3C ).
CaMKIIa Interacts with D3Rs In Vivo
D3Rs are enriched in accumbal neurons. To determine whether native CaMKIIa and D3Rs interact with each other in these neurons, coimmunoprecipitation was performed using the solubilized synaptosomal fraction (P2) from the rat NAc. A clear and specific band of CaMKIIa, but not CaMKIV, was shown in the D3R precipitates ( Figure 5A ). No immunoreactivity of other key synaptic proteins, including postsynaptic density (PSD)-93, PSD-95, synapse-associated protein (SAP) 97, and SAP102, was detected in the D3R precipitates (data not shown). In a reverse coimmunoprecipitation assay, a D3R-specific band was seen in the CaMKIIa precipitates ( Figure 5B ). CaMKIIa in D3R-expressing neurons of the rat midbrain structures (substantia nigra and ventral tegmental area) and the rat medial mammillary bodies showed no interaction with D3Rs because no coimmunoprecipitation between the two proteins was seen in the P2 fraction from these regions ( Figures 5C and 5D ). In the Tat peptides (5-10 mM) were applied 1 hr prior to ionomycin (10 mM, 15 min). Immunoblots (IB) of CaMKIIa, pCaMKIIa(T286), phosphoserine, or D3Rs were performed on D3R precipitates from drug-treated accumbal slices (E-I). Data are presented as means ± SEM for three or five experiments per group. *p < 0.05 versus vehicle or vehicle + vehicle. +p < 0.05 versus vehicle + ionomycin.
NAc, the coimmunoprecipitation was seen in WT mice, but not in D3R mutant mice ( Figure S4A ). Furthermore, the coimmunoprecipitation occurred in the purified PSD fraction of rat accumbal neurons ( Figure S4B ). These data indicate a regionspecific interaction between CaMKIIa and D3Rs in the NAc in vivo and an interaction that can occur in the PSD. Further evidence supporting the interaction of the two proteins in vivo was obtained from yeast two-hybrid assays. Using D3R IL3 as bait in the yeast two-hybrid system, we found a prominent interaction between D3R IL3 and CaMKIIa ( Figure S4C ). The strong interaction with CaMKIIa was also seen for the D3R IL3 (R210-P239), but not D3R IL3 (Q240-Q375), fragment ( Figure S4C ). To determine whether the CaMKIIa-D3R interaction is subject to the Ca 2+ regulation as was observed in vitro, we tested the interaction in the presence of the Ca 2+ ionophore, ionomycin, in rat striatal/NAc slices. Ionomycin induced a concentrationdependent increase in the amounts of CaMKIIa and pCaMKIIa (T286) in the D3R precipitates ( Figure 5E ). The CaMK inhibitor KN93 (20 mM), which inhibits CaMK by preventing the CaM binding to the enzyme, blocked the ionomycin-induced binding of CaMKIIa ( Figure 5F ) and pCaMKIIa(T286) ( Figure S5 ) to Rat accumbal slices were treated with glutamate (1 or 100 mM/glycine 10 mM), NMDA (1 or 100 mM/glycine 10 mM), FPL64176 (20 mM), or SKF83959 (10 mM) alone or with MK801 (10 mM), GYKI52466 (10 mM), KN93 (20 mM), KN92 (20 mM), nifedipine (20 mM), SCH23390 (1 mM), U73122 (20 mM), or U73343 (20 mM) for 15 min. Tat-CaMKIINtide peptides (5 mM) were applied 1 hr prior to SKF83959 (10 mM, 15 min). Immunoblots (IB) of CaMKIIa or D3Rs were performed on D3R precipitates from drug-treated accumbal slices. Data are presented as means ± SEM for four or five experiments per group. *p < 0.05 versus vehicle or vehicle + vehicle. +p < 0.05 versus glutamate (B), FPL64176 (E), or SKF83959 (F). D3Rs. The inactive analog of KN93, KN92, had no effect ( Figures  5F and S5 ). Like KN93, the highly selective CaMKII inhibitory peptide Tat-CaMKIINtide (Chang et al., 1998; Vest et al., 2007) at 5 mM (1 hr before ionomycin) blocked the effect of ionomycin ( Figure 5G ). These results demonstrate a Ca
2+
-sensitive nature of CaMKIIa-D3R interactions in vivo.
To evaluate the role of CaMKIIa-D3R IL3 binding in vivo, we synthesized a Tat-fusion peptide (Tat-D3Rr). The peptide contains a Tat domain (YGRKKRRQRRR) from the human immunodeficiency virus-type 1 (HIV-1) and a CaMKIIa-binding motif (RILTRQNSQCISIRP) from D3R IL3 ( Figure 5H ). The arginine-enriched Tat domain renders cell permeability (Aarts et al., 2002; Mao et al., 2005; Liu et al., 2006) and the CaMKIIa-binding motif competes with D3Rs for CaMKII binding in living neurons. In pull-down assays with biotinylated Tat-fusion peptides, TatD3Rr, but not Tat-D3Rt (a sequence-scrambled control), pulled down recombinant and endogenous CaMKIIa ( Figure S6A ), indicating the ability of Tat-D3Rr to bind to CaMKIIa. Tat-D3Rr (5-10 mM, 1 hr before ionomycin) substantially reduced the ionomycin-stimulated association of the two proteins in striatal/ NAc slices, while Tat-D3Rt did not ( Figure 5H ). Thus, active CaMKIIa was directly recruited to D3R IL3 in response to Ca 2+ rises. Ionomycin was found to increase serine phosphorylation of D3Rs as detected by an antibody selective for phosphoserine ( Figure 5I ). This increase no longer occurred in slices pretreated with Tat-D3Rr ( Figure 5I ) or KN93 ( Figure S6B ), indicating that the interaction of active CaMKIIa with D3R IL3 is required for the ionomycin-stimulated phosphorylation of the receptor. The selectivity of Tat-D3Rr in disrupting the CaMKIIa-D3R interaction was confirmed by the lack of its effect in interfering with the ionomycin-stimulated CaMKIIa interaction with a number of other CaMKII substrates, including NR2B, the cyclin-dependent kinase 5 activator p35, or a-actinin-1 ( Figure S7 ).
To identify the receptors that might provide a Ca 2+ entry to trigger the CaMKIIa association to D3Rs, we tested the effect of glutamate receptor activation on the interaction in NAc slices. Glutamate mimicked the effect of ionomycin in stimulating the CaMKIIa-D3R association ( Figure 6A ). The effect of glutamate was blocked by KN93 and the NMDA receptor antagonist MK801, but not by KN92 and the AMPA receptor antagonist GYKI52466 ( Figure 6B ). Thus, glutamate, through activating NMDA receptors, elevates the CaMKIIa-D3R association. In support of this, NMDA itself induced a concentration-dependent and rapid increase in the association of the two proteins ( Figures  6C and 6D) . FPL64176, an activator of L-type voltage-operated Ca 2+ channels (VOCCs), slightly enhanced the CaMKIIa-D3R interaction, which was blocked by the antagonist nifedipine ( Figure 6E ). Together, VOCCs and especially NMDA receptors can provide a Ca 2+ entry to trigger the CaMKIIa-D3R association.
Activation of phosphatidylinositol (PI)-linked D1Rs (Gaqcoupled) rather than classical cAMP-linked D1Rs (Gas-coupled) elicits the Ca 2+ release from intracellular stores through a phospholipase Cb (PLCb)-dependent and adenylyl-cyclase-independent mechanism (Felder et al., 1989; Undie and Friedman, 1990) . To determine if the Ca 2+ release induced by activating PI-linked D1Rs affects the CaMKIIa-D3R interaction, we examined the effect of activating these receptors on the interaction of the two proteins in NAc slices. Pharmacological activation of PI-linked D1Rs with a selective agonist SKF83959 (Jin et al., 2003) increased the interaction of CaMKIIa with D3Rs ( Figure 6F ). This increase was blocked by the D1R antagonist SCH23390, the amino steroid PLCb inhibitor U73122 (but not its inactive analog U73343), and Tat-CaMKIINtide ( Figure 6F ). Thus, the Ca 2+ release by PI-linked D1Rs possesses the ability to upregulate the CaMKIIa-D3R interaction. The previous data showing the selective activation of CaMKII by PI-linked, but not cAMP-linked, D1Rs (Zhen et al., 2004 ) support this notion.
CaMKIIa-D3R IL3 Interactions Downregulate D3R Function
Activation of D3Rs inhibits the adenylyl-cyclase-mediated cAMP formation (Ahlgren-Beckendorf and Levant, 2004; Jeanneteau et al., 2006) . We next investigated whether the binding of CaMKII to D3R IL3 alters the D3R function in inhibiting cAMP formation. In rat accumbal slices, the adenylyl cyclase activator forskolin (1 mM, 20 min) markedly elevated cAMP levels above a baseline of 4.1 ± 0.3 pmol/ml. A D3R selective agonist PD128907 at low concentrations (1-3 nM) significantly reduced the forskolin-activated cAMP accumulation ( Figure 7A ). The selectivity of PD128907 was demonstrated by the observation that the agonist, when applied at these sufficiently low concentrations, did not alter the forskolin effect in slices from D3R mutant mice ( Figure S8 ). Cotreatment with ionomycin (10 mM) antagonized the effect of PD128907 ( Figure 7A ). The effect of ionomycin was sensitive to KN93 and Tat-CaMKIINtide but not KN92 ( Figure 7A ). Furthermore, Tat-D3Rr (8 mM, 1 hr prior to ionomycin/PD128907) attenuated the effect of ionomycin while Tat-D3Rt did not (Figure 7B ). Neither Tat-D3Rr nor Tat-D3Rt had any effect on the forskolin-stimulated cAMP formation or on the inhibition of forskolin-stimulated cAMP formation by PD128907 (data not shown). These data indicate that Ca 2+ -activated CaMKII associates with D3Rs and reduces D3R efficacy in inhibiting cAMP production.
More experiments were performed in accumbal slices to evaluate the role of CaMKII in regulating dopamine-mediated cAMP signaling. We found that dopamine (5 mM) consistently elevated cAMP levels. This elevation was reduced by Tat-D3Rr ( Figure 7C ). Thus, CaMKII-D3R interactions inhibit the cAMP response to dopamine. Tat-D3Rr alone did not alter basal cAMP levels ( Figure 7C) , suggesting a minimal impact of CaMKIIa-D3R IL3 interactions to D3R function under basal conditions, in which relatively lower levels of basal CaMKIIa-D3R IL3 binding would be anticipated. It is noteworthy that the dopamine concentration (5 mM) applied here is within the physiological PD128907 (1-3 nM), ionomycin (10 mM with 1 mM CaCl 2 ), KN93 (20 mM), KN92 (20 mM), SCH23390 (1 mM), and/or NGB2904 (50 nM) were cotreated with forskolin (1 mM, 20 min) or dopamine (5 mM, 20 min) in (A)-(D). In the experiments in which the Tat-fusion peptide (Tat-CaMKIINtide, Tat-D3Rr, or Tat-D3Rt) was employed, the peptide at 5 mM (A), 1 and 8 mM (B), or 8 mM (C, E, F, and H) was applied 1 hr prior to forskolin (A and B), dopamine (C, E, and F), or SKF81297 (H). SKF81297 was incubated at 10 mM for 5-10 min (G and H). Data are presented as means ± SEM for five to seven experiments per group. *p < 0.05 versus forskolin alone (A and B) , vehicle (G), or vehicle + vehicle (C-F and H). +p < 0.05 versus PD128907 + forskolin (A and B), vehicle + dopamine (C-F), or vehicle + SKF81297 (H).
range of evoked dopamine release in striatal slice preparations (Jones et al., 1998) . In separate experiments, the D1R antagonist SCH23390 blocked the dopamine-stimulated cAMP response ( Figure 7D ), indicating that D1R activation largely mediates the positive cAMP response to dopamine. In contrast to the D1R antagonist, the highly selective D3R antagonist NGB2904, when incubated at 50 nM (EC 50 of 14.4 nM and 1280.0 nM for D3 and D2 receptors, respectively; Yuan et al., 1998; Grundt et al., 2005) , slightly increased the cAMP response to dopamine (although p > 0.05, Figure 7D ). NGB2904 alone increased basal (I) Tat-D3Rr attenuated the cocaine-stimulated locomotion in WT, but not in D3R mutant, mice. Cocaine (20 mg/kg, i.p.) was injected 60 or 90 min after an intra-accumbal injection (15 pmol/0.4 ml) or a systemic injection (3 nmol/g i.v. for rats, and 10 nmol/g i.p. for mice) of Tat peptides, respectively. Data are presented as means ± SEM (n = 4-14 per group). *p < 0.05 versus saline + saline. +p < 0.05 versus saline + cocaine. cAMP concentrations, indicating a tonic D3R activity in inhibiting basal cAMP formation.
CaMKII-D3R interactions further impact downstream effectors of cAMP/protein kinase A (PKA). In accumbal slices, as shown in Figure 7E , Tat-D3Rr markedly reduced the dopamine-stimulated phosphorylation of cAMP-responsive element binding protein (CREB), a nuclear transcription factor downstream of PKA activation, in accumbal lysates. Tat-D3Rr also reduced the dopamine-stimulated expression of c-Fos, an immediate early gene downstream of CREB ( Figure 7F ). In addition to CREB and c-Fos, we examined another target of PKA at excitatory synapses. PKA phosphorylated AMPA receptor GluR1 subunits at serine 845 (S845) in mouse striatal slices treated with the D1R agonist SKF81297 (Snyder et al., 2000) . Similarly, we observed that SKF81297 increased protein levels of phospho-GluR1 at S845 (pGluR1-S845) in synaptosomal fractions from rat accumbal slices ( Figure 7G) . A higher level of pGluR1-S845 was also seen in the PSD fraction ( Figure 7G ), confirming that the event occurred at synaptic sites. Tat-D3Rr was able to reduce the SKF81297-stimulated GluR1 phosphorylation in synaptosomes ( Figure 7H ), indicating that D3Rs are restored to inhibit the PKA-mediated GluR1 phosphorylation. Together, our observations demonstrate that CaMKII inhibits D3R function. As illustrated in Figure 7I , under basal conditions, CaMKII interacts with D3Rs at a low level. D3Rs, due to their higher affinity for dopamine than D1/D2 receptors (Sokoloff et al., 1992) , are activated by basal levels of dopamine to inhibit adenylyl cyclase. When dopamine release is enhanced, the inhibitory tone of D3Rs is suppressed by the Ca 2+ -induced interaction of CaMKII with D3R IL3 , which, in concert with D1R stimulation, augments the cAMP/PKA response to dopamine.
A further attempt was made to explore a possible role of our CaMKIIa-D3R interaction model in modulating another key downstream effector of D3Rs. D3Rs expressed in heterologous cells activate extracellular signal-regulated kinases 1 and 2 (ERK1/2 or p44/p42) via the Gbg pathway (Cussac et al., 1999; Beom et al., 2004) . In HEK293 cells transiently transfected with D3Rs, we found a similar transient increase in ERK1/2 phosphorylation following dopamine application ( Figure S9A ). This was blocked by NGB2904, confirming the role of D3Rs in mediating this event ( Figure S9B ). Noticeably, in HEK293 cells cotransfected with D3Rs and CaMKIIa, ionomycin (2 mM) reduced the dopaminestimulated ERK2 phosphorylation ( Figure S9C ). Tat-D3Rr, but not Tat-D3Rt, reversed the effect of ionomycin ( Figure S9C ). In accumbal slices, D3Rs were activated by PD128907. This activation increased ERK2 phosphorylation in synaptosomal fractions, which was reduced by ionomycin ( Figure S9D ). Tat-D3Rr antagonized the effect of ionomycin, while Tat-D3Rt did not ( Figure S9D ). These data indicate that the interaction of CaMKIIa with D3Rs suppresses the ability of D3Rs to phosphorylate ERK1/2 in heterologous cells and neurons.
CaMKIIa-D3R IL3 Interactions Suppress the D3R-Mediated Inhibition of Motor Activity
We extended our molecular observations to behavioral experiments to investigate whether regulated CaMKIIa-D3R IL3 interactions modulate behavioral responsiveness to dopamine stimulation. Cocaine is known to stimulate motor activity through a mechanism that results in elevated synaptic dopamine levels. Given that postsynaptic D3Rs are generally inhibitory to stimulant-induced motor activity (Xu et al., 1997; Bahi et al., 2005; Richtand, 2006; Pritchard et al., 2007) , we speculated that cocaine would suppress D3Rs by enhancing the interaction of CaMKIIa with D3Rs, which participates in the regulation of the motor response to cocaine. Consistent with this model, cocaine at 20 mg/kg markedly increased the formation of CaMKIIa-D3R IL3 complexes in the rat NAc ( Figure 8A) . A slight increase in this complex formation was induced by cocaine at 5 mg/kg (19.3% ± 0.03% over control). The effect of cocaine (20 mg/kg) was blocked by pretreatment with an intravenous (i.v.) injection of the interfering peptide Tat-D3Rr (3 nmol/g, 1.5 hr before cocaine). The control peptide (Tat-D3Rt) had no effect. Using fluorescently tagged peptides (FITC-Tat-D3Rr), the dynamic presence of these systemically active and cell-permeable peptides in striatal tissues was demonstrated after a single injection ( Figure 8B ). Intracellular uptake of a FITC-Tat-D3Rr peptide, but not a control peptide containing HIV-1 Tat residues 38 to 48 (KALGISYGRKK; Tat38-48) that lie outside the transduction domain, was evident in accumbal neurons following an i.v. injection ( Figure 8C ). Interestingly, in open field locomotor activity assays, Tat-D3Rr, but not Tat-D3Rt, reduced the horizontal activity induced by cocaine (20 mg/kg) while neither peptide had any effect on spontaneous locomotion (Figures 8D-8F ). To determine whether the effect of systemic peptides primarily occurs in the local NAc, a microinjection study targeting the NAc was performed in freely moving rats. A local injection of Tat-D3Rr (15 pmol, 1 hr prior to cocaine) produced the same effect as that observed following a systemic injection ( Figures  8G and 8H) . Additionally, an intra-accumbal injection of KN93, but not KN92 (10 nmol), reduced the effect of cocaine on the formation of CaMKIIa-D3R complexes (data not shown). In WT mice, Tat-D3Rr reduced the cocaine-stimulated locomotion whereas no such effect was observed in D3R mutant mice ( Figure 8I ). Together, these results support a model in which cocaine recruits CaMKIIa to D3Rs to downregulate the D3R function in inhibiting motor responses to cocaine, which ultimately enhances behavioral sensitivity to cocaine stimulation.
DISCUSSION
In this study, we uncover a protein-protein interaction between CaMKIIa and D3Rs in accumbal neurons. The interaction is region-selective since it did not occur in other brain areas, including the substantia nigra and the ventral tegmental area. The interaction involves the consensus CaMKII-binding sequence (I/L)XRXX(S/T) The NMDA receptor was the first receptor that was identified to be bound by CaMKIIa at synaptic sites (Gardoni et al., 1998; Leonard et al., 1999) . In response to Ca 2+ influx, CaMKIIa is recruited to the PSD of excitatory synapses by its increased association with the NMDA receptor NR2B subunit (Strack et al., 1997; Colbran, 2004; Bayer et al., 2006) . The Ca 2+ -evoked CaMKIIa-D3R interaction identified in the current work suggests a new recruiter of CaMKII to the PSD. This is supported by the distribution of abundant D3Rs in the purified PSD (this study). The fact that multiple synaptic receptors interact with CaMKII and recruit it to presumably distinct submembranous microdomains is in good accordance with the multivalent and multifunctional nature of holoenzymes and with the high abundance of the enzyme at synaptic sites.
The D3R IL3 is a critical region for Gai/o-coupling (Ilani et al., 2002) , and activation of D3Rs inhibits adenylyl cyclase in heterologous cells (Ahlgren-Beckendorf and Levant, 2004; Sokoloff et al., 2006) . In accumbal neurons, the D3R-mediated inhibition of forskolin-stimulated cAMP accumulation was established in this study. Notably, the D3R efficacy was subject to the regulation by Ca 2+ because the cytoplasmic Ca 2+ rise induced by an ionophore reversed the effect of a D3R agonist. This Ca 2+ regulation relies on the CaMKII activation and the subsequent association of activated CaMKII with D3Rs as demonstrated by the findings that both the CaMKII activation inhibitors (KN93 and CaMKIINtide) and Tat-D3Rr, which disrupted the CaMKIIa-D3R IL3 binding, antagonized the effect of the Ca 2+ ionophore.
Together, the Ca 2+ -triggered recruitment of CaMKII to D3Rs suppresses the D3R efficacy and thus relieves the inhibitory tone of D3Rs on the adenylyl cyclase/cAMP cascade. In this model, a state-dependent nature of CaMKII regulation is recognized (see Figure 7I ). Under basal conditions, the regulation is less significant due to a lower level of CaMKII binding to D3Rs. As a result, D3Rs become tonically active in inhibiting cAMP production. Of note, the D3R is the only subtype with an affinity (Ki = 30 nM; Sokoloff et al., 1992) within the nanomolar range of basal dopamine concentrations at synapses (50 nM; Ross, 1991) . This allows D3Rs to respond to baseline dopamine. When transformed to a stimulated state in which the synaptic dopamine level is increased to the micromolar range, CaMKII is recruited to D3Rs by Ca 2+ to depress the D3R efficacy. This, in concert with the simultaneously activated D1 efficacy in the same neurons (Surmeier et al., 1996; Ridray et al., 1998) , would produce a net upregulation of the cAMP-PKA pathway and its downstream effects, including CREB phosphorylation, c-Fos expression, and AMPA receptor phosphorylation (Snyder et al., 2000; Zhang et al., 2004; Jiao et al., 2007) . The CaMKII-D3R coupling discovered here suggests a new model of the integration of limbic dopamine signals under basal and stimulated conditions. D1R activation contributes to cocaine-stimulated motor activity. In response to cocaine, synaptic dopamine levels are increased, which in turn activates D1Rs on striatonigral neurons.
Through cAMP/PKA, D1Rs enhance excitability of these neurons to glutamate, thereby increasing outflow of the direct striatonigral pathway and motor activity (Surmeier et al., 2007) . In contrast to D1Rs, D3Rs inhibit the cAMP-PKA pathway. Thus, D3Rs are believed to exert an inhibitory effect on dopamine-mediated motor activity. Indeed, D3R mutant mice displayed hyperactivity in a novel environment (Accili et al., 1996; Xu et al., 1997) , indicating an inhibitory tone of postsynaptic D3Rs on normal motor activity (Koeltzow et al., 1998) . D3Rs also suppress motor responsiveness to cocaine as evidenced by the fact that cocaine at a low dose (5 mg/kg) induced a significantly greater motor response in D3R mutant mice than in WT mice (Xu et al., 1997) . Other behavioral studies utilizing D3R mutant mice or D3R-preferring agents generally support this view (Bahi et al., 2005; Richtand, 2006; Pritchard et al., 2007) . However, the D3R-mediated inhibition is subject to downregulation in response to increasing doses of cocaine because cocaine at higher doses (20-40 mg/kg) induced similar increases in motor responses in D3R mutant mice as compared to those of WT mice (Xu et al., 1997) . Indeed, in this study, we observed a suppression of D3R function by cocaine via a mechanism involving CaMKII. This was demonstrated by the findings that (1) cocaine dose-dependently increased the association of CaMKII with D3Rs, and (2) the disruption of this association by Tat-D3Rr restored the ability of D3Rs to suppress the motor response to cocaine (20 mg/kg) in rats and WT mice, but not in D3R mutant mice. Tat-D3Rr also restored the efficiency of D3Rs to inhibit the D1R-mediated phosphorylation of synaptic AMPA receptors at a PKA-sensitive site (S845) in accumbal neurons. Together, through a specific protein-protein interaction between CaMKII and D3Rs, cocaine transiently releases the D3R-mediated ''brake'' on behavioral responses to the stimulant. This dynamic downregulation of D3R function could enhance behavioral sensitivity to cocaine stimulation.
EXPERIMENTAL PROCEDURES Animals
Adult male Wistar rats weighting 200-225 g (Charles River, New York, NY), adult WT mice, and mutant mice lacking D3Rs were individually housed at 23 C and humidity of 50% ± 10% with food and water available ad libitum.
The animal room was on a 12/12 hr light/dark cycle with lights on at 0700. All animal use procedures were in strict accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee.
Protein Extraction
Animals were anesthetized with 2.5%-3% isoflurane and decapitated. Brains were removed and coronal sections were cut. Bilateral punches of the local NAc (core and shell) or other brain regions were obtained using punch corers. Samples were removed into a microtube containing ice-cold sample buffer (20 mM Tris-HCl [pH 7.4], 1 mM dithiothreitol, 10 mM NaF, 2 mM Na 3 VO 4 , 1 mM EDTA, 1 mM EGTA, 5 mM microcystin-LR, and 0.5 mM phenylmethylsulfonyl fluoride), and homogenized by sonication. Homogenates were centrifuged at 700 3 g for 10 min at 4 C. The supernatant was centrifuged at 10,000 3 g at 4 C for 30 min to obtain the P2 pellet (synaptosomal fraction).
The P2 was soluabilized (see Supplemental Experimental Procedures). Protein concentrations in homogenates (lysates) and the P2 pellet were determined.
Cloning, Expression, and Purification of GST-Fusion Proteins
The cDNA fragments encoding the D3R IL2 (D127-R149), D3R IL3 (R210-Q375), D3R IL3 (R210-P239), D3R IL3 (Q240-Q375), D3R IL3 (H269-Q375), D3R IL3 (R345-Q375), D2R IL3 (I210-V270), CaMKIIa CD (L91-S272), CaMKIIa RD (H273-S314),
or CaMKIIa AD (G315-H478) were generated by PCR amplification from full-length cDNA clones. These fragments were subcloned into BamHI-EcoRI sites of the pGEX4T-3 plasmid (Amersham Biosciences, Arlington Heights, IL) or SpeI-XhoI sites of the pET-41a(+) plasmid (Novagen, Madison, WI). Initiation methionine residues and stop codons were also incorporated where appropriate. To confirm appropriate splice fusion, all constructs were sequenced. GST-fusion proteins were expressed in E. coli BL21 cells (Amersham) or BL21(DE3)pLysE cells (Novagen) and purified from bacterial lysates as described by the manufacturer. GST-or His-tagged full-length CaMKIIa (M1-H478) and GST-tagged full-length CaMKIV (M1-Y473) were expressed and purified via a baculovirus/Sf9 insect cell expression system.
Affinity Purification (Pull-Down) Assay Solubilized accumbal extracts (50-100 mg of protein) were diluted with 1X PBS/1% Triton X-100 and incubated with 50% (v/v) slurry of glutathione Sepharose 4B beads (Amersham) saturated with GST alone or with the indicated GST-fusion protein (5-10 mg) for 2-3 hr at 4 C. Beads were washed four times with 1X PBS/1% Triton X-100. Bound proteins were eluted with 2X lithium dodecyl sulfate (LDS) sample buffer, resolved by SDS-PAGE, and immunoblotted with a specific antibody.
In Vitro Binding Assay GST-fusion proteins (1-5 mg) in PBS were digested with 0.2 NIH unit of thrombin (Sigma, St. Louis, MO) for 2 hr at room temperature. The reaction was stopped by adding PMSF (10 mM). GST was removed by glutathione Sepharose (Amersham). The supernatant was equilibrated to binding buffer (200 mM NaCl, 0.2% Triton X-100, 0.1 mg/ml BSA, and 50 mM Tris [pH, 7.5]) with or without 0.5 mM CaCl 2 , 1 mM CaM, 1 mM EGTA, or 50 mM ATP as indicated. In some experiments, His-tagged CaMKIIa WT (57 kDa), WT pCaMKIIa, CaMKIIa mutants (50 kDa), or CaM was used. Binding reactions were initiated by adding purified GST-fusion proteins and were remained at 4 C for 2-3 hr unless otherwise indicated. GST-fusion proteins were precipitated using 100 ml of 10% glutathione Sepharose. The precipitate was washed three times with binding buffer. Bound proteins were eluted with 2X LDS loading buffer, resolved by SDS-PAGE, and immunoblotted with a specific antibody.
cAMP Enzyme Immunoassay After incubation with drugs indicated for 20-30 min at room temperature, accumbal slices were homogenized in 0.1 M HCl solution for 15 min with gentle shaking and spun in the microcentrifuge tubes. cAMP concentration of the supernatant was measured using the Direct cAMP Enzyme Immunoassay (EIA) Kit (Assay Designs, Ann Arbor, MI) following the manufacturer's instruction. Protein concentrations were determined using a BCA Protein Assay kit (Pierce).
Behavioral Assessments
Locomotion in an open field was evaluated as described previously (Liu et al., 2006) .
SUPPLEMENTAL DATA
The supplemental data for this article include nine Supplemental Figures and Supplemental Experimental Procedures and can be found at http://www. neuron.org/supplemental/S0896-6273(08)01086-6.
